The current ratio of 10.01 in 2026Q2 appears robust, yet it is inflated by a surge in cash to $413.0M, likely from a convertible issuance. The prior quarter's cash of $80.2M against a quarterly burn exceeding $50M suggests a runway of less than two quarters, indicating that the current liquidity position is temporary and dependent on capital markets access. Investors should monitor the sustainability of this cash balance, as the quick ratio mirrors the current ratio, reflecting minimal inventory dependence.

The spike in debt-to-equity to 2.70 in 2025Q4, following a period of minimal leverage, suggests a strategic but risky capital raise, likely via convertible notes. With interest coverage consistently negative (e.g., -1.81 in 2025Q4), the company is not generating operating income to service debt, though the cash infusion provides near-term liquidity. The elevated leverage, combined with a negative equity position in some quarters, indicates that the balance sheet is strained and future refinancing may be challenging without dilution or asset sales.

The extreme volatility in DSO and DPO, with DPO exceeding 1000 days in several quarters, indicates that these ratios are driven by the timing of milestone payments and accruals rather than underlying working capital management. The cash conversion cycle is often negative or uncomputable, suggesting that the company is not efficiently converting revenue into cash, but this is a function of the project-based revenue model. Investors should focus on the recurring cash burn rate, which averaged -$42.7M per quarter, as a more reliable indicator of operational efficiency.

The extreme volatility in gross margin, ranging from -78.0% to 93.9%, underscores that reported margins are an artifact of milestone revenue recognition, not a reflection of manufacturing cost structure. The TTM operating margin of -1166.8% indicates that R&D and SG&A expenses far outpace the minimal revenue, consistent with a clinical-stage biotech in heavy investment. The true earning power is negative, and profitability will only emerge if the pipeline assets, such as AMT-130, achieve commercial success, which remains unproven.

The return on invested capital has been consistently negative, with a dramatic worsening to -180.2% in 2026Q2, driven by a large net loss and a relatively small invested capital base. ROE has also been volatile, ranging from -2.5% to -71.7%, indicating that the company is destroying value as it invests heavily in R&D without generating commensurate returns. This pattern is typical for clinical-stage biotechs, but the magnitude of negative returns suggests that the market is pricing in significant future success, which is highly uncertain.